Bond.az White LogoBond.az Black Logo

UBS Downgrades Verra Mobility on Avis Loss

UBS downgrades Verra Mobility after Avis contract termination, slashing price target to $4. Stock down 71% in a week.

Olivia Taylor
ByOlivia Taylor- Senior Editor
|
0

UBS downgraded Verra Mobility (NASDAQ:VRRM) from Buy to Neutral and cut its price target to $4.00 from $23.00 after the termination of the contract with Avis Budget. The stock now trades at $3.85, down 71% over the past week and 82% over six months.

The contract loss is expected to reduce Verra Mobility's 2026 annualized revenue by $135-$145 million and EBITDA by $120-$125 million before cost cuts. This represents roughly 14% of prior 2026 revenue guidance and 30% of EBITDA guidance. The company reported $358 million in EBITDA over the last twelve months with a 57% gross profit margin.

UBS reduced its 2027-2028 EBITDA estimates by 27%-36% due to the Avis contract loss and uncertainty around renewals. Analysts cited potential pricing pressure, offset partly by cost reductions. Verra Mobility's contracts with Hertz and Enterprise are up for renewal in Q2 and Q4 2027, respectively.

Following the news, Verra Mobility revised its 2026 outlook: revenue $985-$995 million, adjusted EBITDA $380-$385 million. Multiple analysts downgraded the stock, including William Blair, Deutsche Bank, and Baird. The company is taking immediate cost-cutting steps.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
731

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
UBS Downgrades Verra Mobility on Avis Loss | Bond.az